DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0042898A1 Berenson Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0042898A1 Berenson Et Al US 20170042898A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0042898A1 Berenson et al. (43) Pub. Date: Feb. 16, 2017 (54) METHODS AND COMPOSITIONS FOR Publication Classification TREATINGVIRAL OR VIRALLY-INDUCED (51) Int. Cl. CONDITIONS A63L/506 (2006.01) A6IR 9/00 (2006.01) (71) Applicants: HEMAQUEST A638/12 (2006.01) PHARMACEUTICALS, INC., San A6II 3/19 (2006.01) Diego, CA (US); TRUSTEES OF A6II 3/18 (2006.01) BOSTON UNIVERSITY, Boston, MA A6II 3/167 (2006.01) (US) A63L/4045 (2006.01) (72) Inventors: Ronald J. Berenson, Mercer Island, A6II 3/165. (2006.01) WA (US); Douglas V. Faller, Weston, A638/15 (2006.01) A6II 3/4402 (2006.01) MA (US) A6II 3/522 (2006.01) (73) Assignees: HEMAQUEST A6II 3/473 (2006.01) PHARMACEUTICALS, INC., San (52) U.S. Cl. Diego, CA (US); TRUSTEES OF CPC ........... A61 K3I/506 (2013.01); A61 K3I/522 BOSTON UNIVERSITY, Boston, MA (2013.01); A61K 9/0053 (2013.01); A61 K (US) 38/12 (2013.01); A61K 31/19 (2013.01); A61 K 3 1/473 (2013.01); A61K 31/167 (2013.01); (21) Appl. No.: 15/335,776 A61K 31/4045 (2013.01); A61K 3 1/165 (2013.01); A61K 38/15 (2013.01); A61 K (22) Filed: Oct. 27, 2016 3I/4402 (2013.01); A61K 31/18 (2013.01) Related U.S. Application Data (63) Continuation of application No. 14/728,592, filed on (57) ABSTRACT Jun. 2, 2015, now abandoned, which is a continuation of application No. 13/912,637, filed on Jun. 7, 2013, Provided are methods and compositions for the prevention now abandoned, which is a continuation of applica and/or treatment of viral conditions, virally-induced condi tion No. 13/046,555, filed on Mar. 11, 2011, now tions and inflammatory conditions. The methods can com abandoned. prise administering to a Subject a viral inducing agent with (60) Provisional application No. 61/430.931, filed on Jan. an antiviral agent, and optionally an additional agent. The 7, 2011, provisional application No. 61/313,052, filed viral inducing agent can be a HDAC inhibitor administered on Mar. 11, 2010. orally. Patent Application Publication Feb. 16, 2017 Sheet 1 of 21 US 2017/0042898A1 F.G. 1A FIG. 1B Patent Application Publication Feb. 16, 2017 Sheet 2 of 21 US 2017/0042898A1 12 8- xxxx xx t - i. w 3s s. :x s x GC Concertationsi s W 8. 8 :- 2 -- ---- assa &aasaxx-xx-xxxx -- acces:-- ---- &xas. i. e. wasy a k e - 3 x Patent Application Publication Feb. 16, 2017 Sheet 3 of 21 US 2017/0042898A1 F.G. 2C N 3. treated Drug only Cy Cy FIG. 2D 8 . 8x 3 2. ss t; P05 x x x s x e x 5 w: & s C. POV only fixi:3+Cy Patent Application Publication Feb. 16, 2017 Sheet 4 of 21 US 2017/0042898A1 FIG. 3A 8 Mock 10 mM 2.5 mM 50mM sia: a. ^i: Drug E. Drug-GCV 8. 8 ick I Drug Drug-GCV Patent Application Publication Feb. 16, 2017 Sheet 5 of 21 US 2017/0042898A1 2. c. -- - - - - - - Untreated 1mMValproic 2mM valproic 1mMNaB cit Acid Patent Application Publication Feb. 16, 2017 Sheet 6 of 21 US 2017/0042898A1 FIG. 4A 1. 8. f 600 3500 3400 3 - 17, ... 27% "*8...a3. Si said. Drug Only Drug-GCV 3. x s: x. x Untreated Scriptaid500 nM Scriptaic Scriptaic2u M. Patent Application Publication Feb. 16, 2017 Sheet 7 of 21 US 2017/0042898A1 F.G. 5A Saves X. ro- syssessesssssssss 5. SA-A. SAA SAA Drug Only Drug-GCW Patent Application Publication Feb. 16, 2017 Sheet 8 of 21 US 2017/0042898A1 *s 8: : x E3 E3 s: s w- trait 8.x wo. Dug Only Drugi-GCV Patent Application Publication Feb. 16, 2017. Sheet 9 of 21 US 2017/0042898A1 Patent Application Publication Feb. 16, 2017. Sheet 10 of 21 US 2017/0042898A1 xxx orro st-r- ssssssssssssssss s xx w w; treat: Oxanatin Oxantiatin Oxanatin a. S; Without GCV Patent Application Publication Feb. 16, 2017. Sheet 11 of 21 US 2017/0042898A1 r o 150 s: & 100 * - 5% :::::::: treated Apicidin Acid s without GCV ity Patent Application Publication Feb. 16, 2017. Sheet 13 of 21 US 2017/0042898A1 FG 1 OC 28 Y-8s: 2 ww --- 8. & as & s s s x: s : x: x x: Drug Only it 8 Patent Application Publication Feb. 16, 2017. Sheet 14 of 21 US 2017/0042898A1 Patent Application Publication Feb. 16, 2017. Sheet 15 of 21 US 2017/0042898A1 No. Patent Application Publication Feb. 16, 2017. Sheet 16 of 21 US 2017/0042898A1 F.G. 12A it. Of it (Cy Li C2 ***************************************************** Drug Ony C. Patent Application Publication Feb. 16, 2017. Sheet 17 of 21 US 2017/0042898A1 F.G. 12C §@º (nooreo at:~)pºleºnun c)ejwºdzo-decz „………………………No.Wº?º?-gºc? Drug Only Cf F.G. 12D Drug Only is {f Patent Application Publication Feb. 16, 2017. Sheet 18 of 21 US 2017/0042898A1 F.G. 12E 2s - Dug Oriy 3 Of F.G. 12F seºrºco• Patent Application Publication Feb. 16, 2017. Sheet 20 of 21 US 2017/0042898A1 F.G. 14 8. : Patent Application Publication Feb. 16, 2017. Sheet 21 of 21 US 2017/0042898A1 US 2017/0042898 A1 Feb. 16, 2017 METHODS AND COMPOSITIONS FOR SUMMARY OF THE INVENTION TREATINGVIRAL OR VIRALLY-INDUCED 0006. In one aspect, a method for treating and/or pre CONDITIONS venting a viral condition, a virally-induced condition, or an inflammatory condition comprising administering a histone CROSS-REFERENCE TO RELATED deacetylase inhibitor (HDAC inhibitor) and an antiviral APPLICATIONS agent wherein the HDAC inhibitor is a pyrimidine 0001. This application is a continuation application of hydroxamic acid derivative is provided. co-pending U.S. patent application Ser. No. 14/728,592 filed 0007. In another aspect, a method for treating and/or Jun. 2, 2015, which is a continuation application of U.S. preventing a viral or virally-induced condition is provided patent application Ser. No. 13/912,637 filed Jun. 7, 2013, comprising administering a HDAC inhibitor and an antiviral which is a continuation application of U.S. patent applica agent wherein the viral or virally-induced condition is tion Ser. No. 13/046,555 filed on Mar. 11, 2011, which caused by a DNA virus and the HDAC inhibitor is admin claims the benefit under 35 U.S.C. 119(e) of U.S. Provi istered at dose of less than 2 mg/kg per dose. sional Application No. 61/430,931 filed on Jan. 7, 2011, and 0008. In yet another aspect, a method for treating and/or U.S. Provisional Application No. 61/313,052 filed on Mar. preventing a viral condition, a virally-induced condition, or 11, 2010, the contents of each of which are incorporated an inflammatory condition is provided comprising adminis herein by reference in their entireties. tering a HDAC inhibitor and an antiviral agent wherein the MW of the HDAC inhibitor is greater than 275 g/mol. SEQUENCE LISTING 0009. In another aspect, a method for treating and/or preventing a viral condition or a virally-induced condition is 0002 The instant application contains a Sequence Listing provided, comprising administering a HDAC inhibitor which has been submitted in ASCII format via EFS-Web and wherein the HDAC inhibitor is a pyrimidine hydroxamic is hereby incorporated by reference in its entirety. Said acid derivative. ASCII copy, created on Oct. 26, 2016, is named 701586 0010. In another aspect, a composition comprising a (i) 070083. SL.txt and is 1,296 bytes in size. HDAC inhibitor and (ii) an antiviral agent is provided, wherein the HDAC inhibitor is a pyrimidine hydroxamic BACKGROUND OF THE INVENTION acid derivative. 0011 Provided herein, in one aspect, is a method for 0003. Many patients can have latent infections in which treating and/or preventing a viral or virally-induced condi a virus is present but is not expressing viral proteins such as tion comprising administering a HDAC inhibitor and an viral thymidine kinase or protein kinase, the target for antiviral agent wherein the viral or virally-induced condition common anti-viral drugs such as acyclovir and ganciclovir. is caused by a DNA virus and the HDAC inhibitor is A viral inducing drug such as a histone deacetylase inhibitor administered at dose of less than 2 mg/kg per dose. In some (HDAC inhibitor HDACi) can be used to re-induce the embodiments, the HDAC inhibitor is Vorinostat/suberoyl expression of viral thymidine kinase or protein kinase in anilide hydroxamic acid, JNJ-26481585 (N-hydroxy-2-(4- viral infected cells in the subject; the subject can then be ((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperi treatment with antiviral drugs to eliminate latent viral infec din-1-yl)pyrimidine-5-carboxamide), R306465/JNJ tions. As EBV and/or other latent viral infections can be 1624 11.99 (N-hydroxy-5-(4-(naphthalen-2-ylsulfonyl) associated with a variety of conditions, many of which are piperazin-1-yl)pyrimidine-2-carboxamide), CHR-3996 (2- inflammatory conditions, such as lymphomas, autoimmune (6-(6-Fluoroquinolin-2-yl)methylamino-3-azabicyclo conditions, allergic conditions, eliminating the latent virus 3.1.0 hex-3-yl)-N-hydroxypyrimidine-5-carboxamide), with this therapy can be used to prevent or treat such Belinostat/PXD101, Panobinostat/LBH-589, trichostatin conditions. A/TSA (7-4-(dimethylamino)phenyl-N-hydroxy-4,6-dim 0004 EBV can induce autoimmune conditions through a ethyl-7-oxohepta-2,4-dienamide), ITF2357, CBHA, Givi number of potential mechanisms, e.g.: 1) activating B cells nostat/ITF2357, romidepsin (IstodaxTM), PCI-24781, depsi to produce auto-antibodies, 2) turning on T cells that attack peptide (FR901228 or FK228), butyrate, phenylbutyrate, host tissue, 3) molecular mimicry in which EBV antigens valproic acid, AN-9, CI-994, Entinostat/MS-275, SNDX cross react with host antigens such that autoimmune condi 275, mocetinostat/MGCD0103 (N-(2-aminophenyl)-4-((4- tion results when T cells or antibodies reactive with these pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide), antigens cross react with host antigens causing damage to m-carboxycinnamic acid, bishydroxamic acid, Suberic bis host tissues, 4) EBV infected B cells produce cytokines hydroxamic acid, oxamflatin, ABHA, SB-55629, pyroxam which turn on other elements of the immune system and ide, propenamides, aroyl pyrrolyl hydroxamides, and increase inflammation which can also exacerbate autoim LAQ824 (((E)-N-hydroxy-3-4-2-hydroxyethyl-2-(1H mune condition, 5) EBV infected B or T cells can become indol-3-yl)ethylaminomethylphenylprop-2-enamide).
Load more

Recommended publications
  • Histone Deacetylase Inhibitors: an Attractive Therapeutic Strategy Against Breast Cancer
    ANTICANCER RESEARCH 37 : 35-46 (2017) doi:10.21873/anticanres.11286 Review Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer CHRISTOS DAMASKOS 1,2* , SERENA VALSAMI 3* , MICHAEL KONTOS 4* , ELEFTHERIOS SPARTALIS 2, THEODOROS KALAMPOKAS 5, EMMANOUIL KALAMPOKAS 6, ANTONIOS ATHANASIOU 4, DEMETRIOS MORIS 7, AFRODITE DASKALOPOULOU 2,8 , SPYRIDON DAVAKIS 4, GERASIMOS TSOUROUFLIS 1, KONSTANTINOS KONTZOGLOU 1, DESPINA PERREA 2, NIKOLAOS NIKITEAS 2 and DIMITRIOS DIMITROULIS 1 1Second Department of Propedeutic Surgery, 4First Department of Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 2N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 3Blood Transfusion Department, Aretaieion Hospital, Medical School, National and Kapodistrian Athens University, Athens, Greece; 5Assisted Conception Unit, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 6Gynaecological Oncology Department, University of Aberdeen, Aberdeen, U.K.; 7Lerner Research Institute, Cleveland Clinic, Cleveland, OH, U.S.A; 8School of Biology, National and Kapodistrian University of Athens, Athens, Greece Abstract. With a lifetime risk estimated to be one in eight in anticipate further clinical benefits of this new class of drugs, industrialized countries, breast cancer is the most frequent
    [Show full text]
  • Hepatitis Virus in Long-Fingered Bats, Myanmar
    DISPATCHES Myanmar; the counties are adjacent to Yunnan Province, Hepatitis Virus People’s Republic of China. The bats covered 6 species: Miniopterus fuliginosus (n = 640), Hipposideros armiger in Long-Fingered (n = 8), Rhinolophus ferrumequinum (n = 176), Myotis chi- nensis (n = 11), Megaderma lyra (n = 6), and Hipposideros Bats, Myanmar fulvus (n = 12). All bat tissue samples were subjected to vi- Biao He,1 Quanshui Fan,1 Fanli Yang, ral metagenomic analysis (unpublished data). The sampling Tingsong Hu, Wei Qiu, Ye Feng, Zuosheng Li, of bats for this study was approved by the Administrative Yingying Li, Fuqiang Zhang, Huancheng Guo, Committee on Animal Welfare of the Institute of Military Xiaohuan Zou, and Changchun Tu Veterinary, Academy of Military Medical Sciences, China. We used PCR to further study the prevalence of or- During an analysis of the virome of bats from Myanmar, thohepadnavirus in the 6 bat species; the condition of the a large number of reads were annotated to orthohepadnavi- samples made serologic assay and pathology impracticable. ruses. We present the full genome sequence and a morpho- Viral DNA was extracted from liver tissue of each of the logical analysis of an orthohepadnavirus circulating in bats. 853 bats by using the QIAamp DNA Mini Kit (QIAGEN, This virus is substantially different from currently known Hilden, Germany). To detect virus in the samples, we con- members of the genus Orthohepadnavirus and represents ducted PCR by using the TaKaRa PCR Kit (TaKaRa, Da- a new species. lian, China) with a pair of degenerate pan-orthohepadnavi- rus primers (sequences available upon request). The PCR he family Hepadnaviridae comprises 2 genera (Ortho- reaction was as follows: 45 cycles of denaturation at 94°C Thepadnavirus and Avihepadnavirus), and viruses clas- for 30 s, annealing at 54°C for 30 s, extension at 72°C for sified within these genera have a narrow host range.
    [Show full text]
  • Cyprinus Carpio
    Académie Universitaire Wallonie - Europe Université de Liège Faculté de Médecine Vétérinaire Département des Maladies Infectieuses et Parasitaires Service d’Immunologie et de Vaccinologie Etude des portes d’entrée de l’Herpèsvirus cyprin 3 chez Cyprinus carpio Study of the portals of entry of Cyprinid herpesvirus 3 in Cyprinus carpio Guillaume FOURNIER Thèse présentée en vue de l’obtention du grade de Docteur en Sciences Vétérinaires Année académique 2011-2012 Académie Universitaire Wallonie - Europe Université de Liège Faculté de Médecine Vétérinaire Département des Maladies Infectieuses et Parasitaires Service d’Immunologie et de Vaccinologie Etude des portes d’entrée de l’Herpèsvirus cyprin 3 chez Cyprinus carpio Study of the portals of entry of Cyprinid herpesvirus 3 in Cyprinus carpio Promoteur : Prof. Alain Vanderplasschen Guillaume FOURNIER Thèse présentée en vue de l’obtention du grade de Docteur en Sciences Vétérinaires Année académique 2011-2012 « La science progresse en indiquant l'immensité de l'ignoré. » Louis Pauwels Remerciements Liège, le 15 février 2012 L’accomplissement d’une thèse est un long et palpitant voyage en océan où se mélangent la curiosité, le doute, la persévérance, et la confiance… en soi bien sûr, mais surtout envers toutes les personnes qui, par leurs conseils, leur aide, leur soutien m’ont permis de mener cette thèse à bien. Je tiens ici à remercier mes collègues, amis et famille qui ont été tantôt les phares, tantôt les boussoles, toujours les fidèles compagnons de cette aventure. Je commencerais par adresser mes plus sincères remerciements à mon promoteur, le Professeur Alain Vanderplasschen, qui m’avait déjà remarqué en amphithéâtre pour ma curiosité, à moins que ce ne soit pour mon irrésistible coiffure..
    [Show full text]
  • Transcriptomic Profiling of Equine and Viral Genes in Peripheral Blood
    pathogens Article Transcriptomic Profiling of Equine and Viral Genes in Peripheral Blood Mononuclear Cells in Horses during Equine Herpesvirus 1 Infection Lila M. Zarski 1, Patty Sue D. Weber 2, Yao Lee 1 and Gisela Soboll Hussey 1,* 1 Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA; [email protected] (L.M.Z.); [email protected] (Y.L.) 2 Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, MI 48824, USA; [email protected] * Correspondence: [email protected] Abstract: Equine herpesvirus 1 (EHV-1) affects horses worldwide and causes respiratory dis- ease, abortions, and equine herpesvirus myeloencephalopathy (EHM). Following infection, a cell- associated viremia is established in the peripheral blood mononuclear cells (PBMCs). This viremia is essential for transport of EHV-1 to secondary infection sites where subsequent immunopathol- ogy results in diseases such as abortion or EHM. Because of the central role of PBMCs in EHV-1 pathogenesis, our goal was to establish a gene expression analysis of host and equine herpesvirus genes during EHV-1 viremia using RNA sequencing. When comparing transcriptomes of PBMCs during peak viremia to those prior to EHV-1 infection, we found 51 differentially expressed equine genes (48 upregulated and 3 downregulated). After gene ontology analysis, processes such as the interferon defense response, response to chemokines, the complement protein activation cascade, cell adhesion, and coagulation were overrepresented during viremia. Additionally, transcripts for EHV-1, EHV-2, and EHV-5 were identified in pre- and post-EHV-1-infection samples. Looking at Citation: Zarski, L.M.; Weber, P.S.D.; micro RNAs (miRNAs), 278 known equine miRNAs and 855 potentially novel equine miRNAs were Lee, Y.; Soboll Hussey, G.
    [Show full text]
  • An Overview of the Role of Hdacs in Cancer Immunotherapy
    International Journal of Molecular Sciences Review Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy Debarati Banik, Sara Moufarrij and Alejandro Villagra * Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, 800 22nd St NW, Suite 8880, Washington, DC 20052, USA; [email protected] (D.B.); [email protected] (S.M.) * Correspondence: [email protected]; Tel.: +(202)-994-9547 Received: 22 March 2019; Accepted: 28 April 2019; Published: 7 May 2019 Abstract: Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combatting cancer, autoimmune, neurodegenerative, and infectious diseases. The same has also encouraged the evaluation of multiple HDACi candidates in preclinical studies in cancer and other diseases as well as the FDA-approval towards clinical use for specific agents. In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis. We have also included a brief overview of the classification of HDACis as well as their various roles in physiological and pathophysiological scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer. Given the critical role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME. We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clinical trials or show promising preclinical effects for future consideration.
    [Show full text]
  • Guide for Common Viral Diseases of Animals in Louisiana
    Sampling and Testing Guide for Common Viral Diseases of Animals in Louisiana Please click on the species of interest: Cattle Deer and Small Ruminants The Louisiana Animal Swine Disease Diagnostic Horses Laboratory Dogs A service unit of the LSU School of Veterinary Medicine Adapted from Murphy, F.A., et al, Veterinary Virology, 3rd ed. Cats Academic Press, 1999. Compiled by Rob Poston Multi-species: Rabiesvirus DCN LADDL Guide for Common Viral Diseases v. B2 1 Cattle Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 2 Deer and Small Ruminants Please click on the principle system involvement Generalized viral disease Respiratory viral disease Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 3 Swine Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 4 Horses Please click on the principle system involvement Generalized viral diseases Neurological viral diseases Respiratory viral diseases Enteric viral diseases Abortifacient/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 5 Dogs Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Back to the Beginning DCN LADDL Guide for Common Viral Diseases v.
    [Show full text]
  • Virus Particle Structures
    Virus Particle Structures Virus Particle Structures Palmenberg, A.C. and Sgro, J.-Y. COLOR PLATE LEGENDS These color plates depict the relative sizes and comparative virion structures of multiple types of viruses. The renderings are based on data from published atomic coordinates as determined by X-ray crystallography. The international online repository for 3D coordinates is the Protein Databank (www.rcsb.org/pdb/), maintained by the Research Collaboratory for Structural Bioinformatics (RCSB). The VIPER web site (mmtsb.scripps.edu/viper), maintains a parallel collection of PDB coordinates for icosahedral viruses and additionally offers a version of each data file permuted into the same relative 3D orientation (Reddy, V., Natarajan, P., Okerberg, B., Li, K., Damodaran, K., Morton, R., Brooks, C. and Johnson, J. (2001). J. Virol., 75, 11943-11947). VIPER also contains an excellent repository of instructional materials pertaining to icosahedral symmetry and viral structures. All images presented here, except for the filamentous viruses, used the standard VIPER orientation along the icosahedral 2-fold axis. With the exception of Plate 3 as described below, these images were generated from their atomic coordinates using a novel radial depth-cue colorization technique and the program Rasmol (Sayle, R.A., Milner-White, E.J. (1995). RASMOL: biomolecular graphics for all. Trends Biochem Sci., 20, 374-376). First, the Temperature Factor column for every atom in a PDB coordinate file was edited to record a measure of the radial distance from the virion center. The files were rendered using the Rasmol spacefill menu, with specular and shadow options according to the Van de Waals radius of each atom.
    [Show full text]
  • Comparative Effect of Various HDAC-Inhibitors In-Vitro on T- Cell Lymphoma Cell Lines Alone and in Combination with Conventional Anti-Cancer Drugs
    Comparative effect of Various HDAC-inhibitors in-vitro on T- Cell Lymphoma cell lines alone and in combination with conventional anti-cancer drugs Arshad H. Banday Mentor:Dr. Francisco Hernandez-Illizaliturri Introduction. T-cell lymphomas are an uncommon and heterogeneous group of non-Hodgkin lymphomas. Historically therapies for these diseases have been borrowed from treatments for other lymphomas. More recently, efforts have be made to identify novel agents for their activity specifically in T-cell lymphomas. A primary example of new agents with specific activity in T-cell lymphomas is the novel class of drug, histone deacetylase inhibitors Vorinostat and romidepsin are currently approved and are in clinical use for the treatment of cutaneous T-cell lymphomas. Intro….. Histones are core structural components of chromatin; DNA is wound around histones, and histones further associate to become and form chromatin. Histone deacetylation inhibitors (HDAC) inhibitors induce accumulation of acetylated histones which leads to relaxation of chromatin structure and promotes access to transcriptional machinery and RNA polymerase HDACi also modify other cancer related proteins. Chromatin Structure Regulates Transcriptional Activity Histone Deacetylase Inhibitors (HDAC Inhibitors) • Cause increased histone acetylation resulting in.. • Uncoiling of chromatin and transcriptional activation of tumor suppressor genes leading to cell cycle arrest and/or apoptosis Currently only Vorinostat is licensed for use in cutaneous T cell lymphoma (CTCL) Genetic
    [Show full text]
  • Poxvirus in a Swine Farm in Italy: a Sporadic Outbreak? O
    Mariano_imp:ok 20-06-2016 11:23 Pagina 219 V. Mariano et al. Large Animal Review 2015; 21: 219-220 219 Poxvirus in a swine farm in Italy: a sporadic outbreak? O V. MARIANOa, A. NARDIa, E. VERGARIa, F. CARLETTIb, L. BARBIERIc, G. CARDETId a Laboratory of Veterinary Diagnostic Disease of Grosseto, Istituto Zooprofilattico Sperimentale del Lazio e della Toscana “M. Aleandri”, Via Europa 30, Grosseto, Italy b Virology Laboratory, National Institute for Infectious Diseases, IRCCS “L. Spallanzani”, Via Portuense 292, 00149 Rome, Italy c Veterinarian freelancer, Grosseto, Italy d Laboratory of Electron Microscopy and Specialistic Virology, Biotechnology Dept., Istituto Zooprofilattico Sperimentale del Lazio e della Toscana “M. Aleandri”, Via Appia Nuova 1411, Rome, Italy SUMMARY The aim of this report is to describe the occurrence of a Swinepox virus (SWPV) outbreak in Central Italy in 2013 and the pos- sibility of its reappearance. SWPV is the only member belonging to the Suipoxvirus genus in the Poxviridae family and it re- presents the etiologic agent of a worldwide disease specific for swine with an affinity for epidermis. In Italy it has been rarely observed. In November 2013 an outbreak was registered in a biological farm of about 110 animals located in Tuscany. Skin le- sions were observed in a group of 3 months old piglets born in the farms from crossbreed animals. The disease affected 50 of the youngest animals. Diagnosis was based on clinical and pathological signs which were pustular lesions at first located mainly around the neck and the ears and in a later stage disseminated all around the body, especially concentrated in the groin and the abdomen.
    [Show full text]
  • Valproic Acid and Its Amidic Derivatives As New Antivirals Against Alphaherpesviruses
    viruses Review Valproic Acid and Its Amidic Derivatives as New Antivirals against Alphaherpesviruses Sabina Andreu 1,2,* , Inés Ripa 1,2, Raquel Bello-Morales 1,2 and José Antonio López-Guerrero 1,2 1 Departamento de Biología Molecular, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain; [email protected] (I.R.); [email protected] (R.B.-M.); [email protected] (J.A.L.-G.) 2 Centro de Biología Molecular Severo Ochoa, Spanish National Research Council—Universidad Autónoma de Madrid (CSIC-UAM), Cantoblanco, 28049 Madrid, Spain * Correspondence: [email protected] Academic Editor: Maria Kalamvoki Received: 14 November 2020; Accepted: 25 November 2020; Published: 26 November 2020 Abstract: Herpes simplex viruses (HSVs) are neurotropic viruses with broad host range whose infections cause considerable health problems in both animals and humans. In fact, 67% of the global population under the age of 50 are infected with HSV-1 and 13% have clinically recurrent HSV-2 infections. The most prescribed antiherpetics are nucleoside analogues such as acyclovir, but the emergence of mutants resistant to these drugs and the lack of available vaccines against human HSVs has led to an imminent need for new antivirals. Valproic acid (VPA) is a branched short-chain fatty acid clinically used as a broad-spectrum antiepileptic drug in the treatment of neurological disorders, which has shown promising antiviral activity against some herpesviruses. Moreover, its amidic derivatives valpromide and valnoctamide also share this antiherpetic activity. This review summarizes the current research on the use of VPA and its amidic derivatives as alternatives to traditional antiherpetics in the fight against HSV infections.
    [Show full text]
  • Molecular Identification and Genetic Characterization of Cetacean Herpesviruses and Porpoise Morbillivirus
    MOLECULAR IDENTIFICATION AND GENETIC CHARACTERIZATION OF CETACEAN HERPESVIRUSES AND PORPOISE MORBILLIVIRUS By KARA ANN SMOLAREK BENSON A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE UNIVERSITY OF FLORIDA 2005 Copyright 2005 by Kara Ann Smolarek Benson I dedicate this to my best friend and husband, Brock, who has always believed in me. ACKNOWLEDGMENTS First and foremost I thank my mentor, Dr. Carlos Romero, who once told me that love is fleeting but herpes is forever. He welcomed me into his lab with very little experience and I have learned so much from him over the past few years. Without his excellent guidance, this project would not have been possible. I thank my parents, Dave and Judy Smolarek, for their continual love and support. They taught me the importance of hard work and a great education, and always believed that I would be successful in life. I would like to thank Dr. Tom Barrett for the wonderful opportunity to study porpoise morbillivirus in his laboratory at the Institute for Animal Health in England, and Dr. Romero for making the trip possible. I especially thank Dr. Ashley Banyard for helping me accomplish all the objectives of the project, and all the wonderful people at the IAH for making a Yankee feel right at home in the UK. I thank Alexa Bracht and Rebecca Woodruff who have been with me in Dr. Romero’s lab since the beginning. Their continuous friendship and encouragement have kept me sane even in the most hectic of times.
    [Show full text]
  • Hr23b Expression Is a Potential Predictive Biomarker for HDAC Inhibitor Treatment in Mesenchymal Tumours and Is Associated with Response to Vorinostat
    The Journal of Pathology: Clinical Research J Path: Clin Res April 2016; 2: 59–71 Original Article Published online 23 December 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/cjp2.35 HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat Michaela Angelika Ihle,1 Sabine Merkelbach-Bruse,1 Wolfgang Hartmann,1,2 Sebastian Bauer,3 Nancy Ratner,4 Hiroshi Sonobe,5 Jun Nishio,6 Olle Larsson,7 Pierre A˚ man,8 Florence Pedeutour,9 Takahiro Taguchi,10 Eva Wardelmann,1,2 Reinhard Buettner1 and Hans-Ulrich Schildhaus1,11* 1 Institute of Pathology, University Hospital Cologne, Cologne, Germany 2 Gerhard Domagk Institute of Pathology, University Hospital M€unster, M€unster, Germany 3 Sarcoma Center, West German Cancer Center, University of Essen, Essen, Germany 4 US Department of Pediatrics, Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH, USA 5 Department of Laboratory Medicine, Chugoku Central Hospital, Fukuyama, Hiroshima, Japan 6 Faculty of Medicine, Department of Orthopaedic Surgery, Fukuoka University, Fukuoka, Japan 7 Department of Oncology and Pathology, The Karolinska Institute, Stockholm, Sweden 8 Sahlgrenska Cancer Centre, University of Gothenburg, Gothenburg, Sweden 9 Faculty of Medicine, Laboratory of Genetics of Solid Tumours, Institute for Research on Cancer and Aging, Nice, France 10 Division of Human Health & Medical Science, Graduate School of Kuroshio Science, Kochi University Nankoku, Kochi, Japan 11 Institute of Pathology, University Hospital G€ottingen, G€ottingen, Germany *Correspondence to: Hans-Ulrich Schildhaus,Institute of Pathology,University Hospital G€ottingen,Robert-Koch-Strasse40,D-37075G€ottingen, Germany.e-mail: [email protected] Abstract Histone deacetylases (HDAC) are key players in epigenetic regulation of gene expression and HDAC inhibitor (HDACi) treatment seems to be a promising anticancer therapy in many human tumours, including soft tissue sar- comas.
    [Show full text]